Tuesday, December 17, 2024
HomeTagsTransplant-Ineligible

Transplant-Ineligible

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses from the Phase 3 MAIA study of DARZALEX in combination with lenalidomide and...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics